Prospective Randomized Study Comparing ePTFE Versus Dacron Graft for Anterior Sector Venous Drainage in Right Lobe Living Donor Liver Transplantation

December 26, 2020 updated by: ATIF TEKIN, Istanbul Medipol University Hospital

Prospective Randomized Study Comparing ePTFE Versus Dacron Graft Donor Liver Transplantation

Living donor liver transplantation (LDLT) using the right lobe (RL) has created a significant increase in graft supply worldwide. However, it is a technically demanding procedure particularly because of the unique functional anatomic characteristics of hepatic venous drainage [1].

Study Overview

Detailed Description

In the absence of an adequate drainage of the anterior sector (AS) veins, the consequent venous congestion in the RL graft may result in impaired graft regeneration, immediate liver dysfunction, and graft loss even in a liver graft of adequate size [2]. To overcome this problem, Lee et al. [3] introduced the concept of modified RL graft in which the branches of the middle hepatic vein (MHV) was drained using interposition vascular grafts. Although, the issue of when and how the MHV branches should be drained has been controversial since then, reconstruction of segment 5 and 8 veins using an interposition graft has become a standard procedure during RL LDLT. The vascular graft of choice in this procedure has been cryopreserved homologous vein graft, which provides excellent patency with low infection risk. However, such grafts are often unavailable, particularly in programs where deceased donors are scarce and surgeons must rely on synthetic grafts such as expanded polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (Dacron®). Since we have developed an "intent-to-drain" policy in our LDLT program, we have been using Dacron grafts exclusively [4]. Although, complications such as early graft thrombosis, graft infection, and hollow viscous migration remain as major concerns, the safety and efficacy of both ePTFE and Dacron grafts in LDLT has been proven [5, 6]. However, to date, none of the previous studies have specifically compared these two different prosthetic materials, addressing graft patency and complication rates in patients undergoing LDLT. The aim of our study is to compare AS venous outflow reconstruction using ePTFE vs. Dacron grafts for their patency and infection rates and outcomes with respect to graft and patient survival in RL LDLT.

Study Type

Interventional

Enrollment (Anticipated)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Istanbul, Turkey, 34214
        • Recruiting
        • Medipol University Faculty of Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Primary Adult Living Donor Liver Transplantation
  2. Right Lobe graft with anterior sector venous outflow reconstruction -

Exclusion Criteria:

  1. Right Lobe graft without anterior sector venous outflow reconstruction
  2. Liver re-transplantation -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ePTFE graft
In this group, anterior sector of the right lobe graft will be reconstructed using ePTFE vascular grafts
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Other Names:
  • Other: Dacron graft
Other: Dacron graft
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
In this group, anterior sector of the right lobe graft will be reconstructed using Dacron vascular grafts
Other Names:
  • Other: Dacron graft

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Graft patency at 6-month posttransplant
Time Frame: 6 months
Graft Patency
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Graft-related complications
Time Frame: One Year
Rate of graft infection
One Year
Graft survival
Time Frame: One year
Morbidity
One year
Patient survival
Time Frame: One Year
Mortality
One Year
Graft regeneration rate
Time Frame: 6 months
Graft regeneration
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Murat Dayangac, M.D., Study Chief

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 2, 2020

Primary Completion (Anticipated)

September 24, 2022

Study Completion (Anticipated)

December 30, 2022

Study Registration Dates

First Submitted

November 23, 2020

First Submitted That Met QC Criteria

December 3, 2020

First Posted (Actual)

December 4, 2020

Study Record Updates

Last Update Posted (Actual)

December 29, 2020

Last Update Submitted That Met QC Criteria

December 26, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • Medipol Transplant

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patency and Infection Rates Due to Usage of PTFE vs.Dacron Grafts

Clinical Trials on Active Comparator: ePTFE graft

3
Subscribe